Page 20«..10..19202122..»

Archive for the ‘Cardiac Stem Cells’ Category

Columbia firm is world's first to market with stem cell drug

A Columbia-based biotechnology company said this week it received the worlds first government approval to market a stem cell drug, in Canada.

Osiris Therapeutics, founded in 1992, spent 17 years developing a stem cell therapy that offers anti-inflammatory and tissue-regeneration properties. The first treatment it has received approval for this week will help treat children whove received bone marrow transplants that their bodies have rejected. The condition, known as acute graft-versus-host disease, or GvHD, is fatal to 80 percent of the children who contract it, the company said.

C. Randal Mills, president and CEO of Osiris, said in a conference call Friday morning that the company has spent the past eight years navigating clinical trials and regulatory paperwork in a mission to be the first approved stem cell treatment in the world.

During the past eight years, we have not wavered from that mission, Mills said. We now need a new mission.

The two-decade path to market for Osiris drug, Prochymal, is par for the course in the biotechnology industry, where a new pharmaceutical is measured in multi-million dollar clinical trials and reviews that take years.

Prochymal is the first off-the-shelf stem cell drug approved for sale, and the first approved for GvHD, the company said. It derives its stem cells, it said, from the bone marrow of healthy adult donors between 18 and 30 years old.

Osiris is a small biotech company, with around 50 employees, in an industry where far larger competitors, with thousands of employees, usually grab the headlines with blockbuster drugs.

Yet Osiris is a key player in the states nascent stem cell therapies industry. Osiris is one of the worlds largest and most advanced stem cell firms, according to testimony provided by the leaders of the Maryland Stem Cell Research Fund this year in the General Assembly.

The taxpayer-subsidized fund doles out millions of dollars a year in grants to promote stem cell research; Osiris, however, has never received a grant from the fund, according to TEDCO.

This week, the fund said it will award $12.4 million in research grants to 40 projects led by university researchers from Johns Hopkins, University of Maryland and other institutions.

Original post:
Columbia firm is world's first to market with stem cell drug

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at …

MONT-SAINT-GUIBERT, Belgium, May 18, 2012 /PRNewswire/ —

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

Andr Terzic, M.D., Ph.D, Director at Center of Regenerative Medicine, Mayo Clinic, the co-lead investigator on the trial, will present new final follow up data on the Company’s stem cell therapy for heart failure, C3BS-CQR-1, which is based on “Cardiopoiesis” proprietary technology. The presentation will be held on Sunday, May 20th in Belgrade, Serbia.

Dr. Christian Homsy, CEO of Cardio3 BioSciences, said: “Being selected to present the final follow-up data in the late breaking clinical trial session at this prestigious cardiology congress highlights the quality of our technology and reiterates our belief in C3BS-CQR-1 as a potential treatment for patients with heart failure, a condition with a significant unmet medical need. We look forward to advancing the product into Phase III.”

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Center Aalst, Belgium.

The Company’s lead product candidate C3BS-CQR-1 is an innovative pharmaceutical product consisting of autologous cardiac progenitor stem cells. C3BS-CQR-1 is based on ground breaking research conducted at Mayo Clinic that allowed discovery of cardiopoiesis, a process to mimic in adult stem cells the natural signals triggered in the early stages of life during the cardiac tissue development. Cardio3 BioSciences has also developed C-Cath, the next-generation injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information contact:

Cardio3 BioSciences: http://www.c3bs.com Dr Christian Homsy, CEOTel : +32-10-39-41-00 Anne Portzenheim, Communication Manager aportzenheim@c3bs.com

View original post here:
Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at …

Pluristem trial finds stem cells improve cardiac dysfunction

Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) today reported that the cardiac function in a diabetic-induced diastolic dysfunction in animals improved following PLacental eXpanded (PLX cells) administration.

The study was conducted as part of the European Commission’s Seventh Framework Program (FP7) in collaboration with Prof. Doctor Carsten Tschope and his staff at the Charite Universitaetsmedizin Berlin, Berlin-Bradenburg Center for Regenerative Therapies (BCRT), Berlin, Germany.

Dr. Tschope said, “Currently, there are limited treatment options for diastolic dysfunction and even fewer options for diabetic induced diastolic dysfunction. This study holds promise that PLX cells might be able to inhibit diabetic induced diastolic dysfunction progression as well as possibly repair the existing damage, hypotheses that will be further explored in future studies.”

Diabetes was induced in thirty-six mice resulting in the development of diastolic heart failure. After seven days, the animals received either PLX cells from two separate batches or placebo (12 subjects in each of the three groups). Ten mice were not treated (controls).

After three weeks, several cardiac parameters were assessed and found to be significantly improved following the treatment with PLX cells. Important measurements included the cardiac ejection fraction and the left ventricular (LV) relaxation time constant, believed to be the best index of LV diastolic function and a determination of the stiffness of the ventricle. Cardiac ejection fraction improved 19%, the left ventricular relaxation time constant fell 16% and stiffness of the ventricle fell 19%.

Administration of either batch of PLX cells also resulted in a significant anti-inflammatory effect.

Pluristem chairman and CEO Zami Alberman said, “As we demonstrated last week with the announcement that our cells successfully treated the seven year old patient suffering from aplastic bone marrow disease, our strategy is to develop a minimally invasive cell therapy solution that can be used to treat a wide range of life-threatening diseases. Our initial testing of a treatment for diastolic heart disease opens a new potential indication where our cells can be used and potentially positions Pluristem as a “first-line of defense” for diastolic dysfunction.”

Pluristem’s share price jumped 5.6% in pre-market trading on Nasdaq to $3.01, giving a market cap of $126.33 million. The share rose 10.6% on the TASE today to NIS 11.50.

Published by Globes [online], Israel business news – http://www.globes-online.com – on May 15, 2012

Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Read more:
Pluristem trial finds stem cells improve cardiac dysfunction

Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter

MONT-SAINT-GUIBERT, Belgium, May 9, 2012 /PRNewswire/ —

The Belgian biotechnology company, Cardio3–BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has received CE Marking (Conformit Europenne) for its intra-myocardial C-Cath Injection Catheter. The CE Mark certifies that C-Cath complies with applicable European health, safety and environmental protection legislation. C-Cath is now available for commercial use in the EU and many other countries where the CE mark allows commercialization.

The C-Cath Injection Catheter is the most advanced device of its kind and was designed to address three key requirements: ease of use, safety and efficacy. During its development Cardio3 BioSciences combined its extensive experience in stem cell therapies and specific knowledge of the properties of heart tissue with key insights from leading cardiologists in the field. C-Cath’s performance is based on its unique needle design as well as unique catheter properties. Previously announced pre-clinical data from a head to head comparison with the ‘best’ injection catheter available until now showed a close to threefold increase in retention of stem cells within the heart muscle in favour of the CCath Injection Catheter. Within a clinical setting, an increased retention rate could allow an increase in efficacy while reducing side effects.-

Dr Christian Homsy,CEOof Cardio3-BioSciences comments on today’s announcement: “Today marks an important milestone for Cardio3 BioSciences and our innovative C-Cath technology. With C-Cath, we developed an advanced injection catheter that meets the requirements of physicians and has the potential to deliver better outcomes for patients. C-Cath demonstrates our commitment to continued innovation in regenerative heart therapy. This is a major step forward in addressing the patient needs for regenerative therapies for the heart and provides physicians with new treatment options.”

About Cardio3 BioSciences

Cardio3-BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3-BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Center Aalst, Belgium.

The Company’s lead product candidate C3BS-CQR-1 is an innovative pharmaceutical product consisting of autologous cardiac progenitor stem cells. C3BS-CQR-1 is based on ground breaking research conducted at Mayo Clinic that allowed discovery of cardiopoiesis, a process to mimic in adult stem cells the natural signals triggered in the early stages of life during the cardiac tissue development. Cardio3-BioSciences has developed C-Cath, the next-generation injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements.We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information contact:

Cardio3 BioSciences http://www.c3bs.com

See the original post here:
Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter

Duke Team Turns Scar Tissue into Heart Muscle Without Using Stem Cells

By Duke Medicine News and Communications

Scientists at Duke University Medical Center have shown the ability to turn scar tissue that forms after a heart attack into heart muscle cells using a new process that eliminates the need for stem cell transplant.

The study, published online April 26 in the journal Circulation Research, used molecules called microRNAs to trigger the cardiac tissue conversion in a lab dish and, for the first time, in a living mouse, demonstrating the potential of a simpler process for tissue regeneration.

If additional studies confirm the approach in human cells, it could lead to a new way for treating many of the 23 million people worldwide who suffer heart failure, which is often caused by scar tissue that develops after a heart attack. The approach could also have benefit beyond heart disease.

“This is a significant finding with many therapeutic implications,” said Victor J. Dzau, MD, a senior author on the study who is James B. Duke professor of medicine and chancellor of health affairs at Duke University. “If you can do this in the heart, you can do it in the brain, the kidneys, and other tissues. This is a whole new way of regenerating tissue.”

To initiate the regeneration, Dzau’s team at Duke used microRNAs, which are molecules that serve as master regulators controlling the activity of multiple genes. Tailored in a specific combination, the microRNAs were delivered into scar tissue cells called fibroblasts, which develop after a heart attack and impair the organ’s ability to pump blood.

Once deployed, the microRNAs reprogrammed fibroblasts to become cells resembling the cardiomyocytes that make up heart muscle. The Duke team not only proved this concept in the laboratory, but also demonstrated that the cell conversion could occur inside the body of a mouse — a major requirement for regenerative medicine to become a potential therapy.

“This is one of the exciting things about our study,” said Maria Mirotsou, PhD, assistant professor of cardiology at Duke and a senior author of the study. “We were able to achieve this tissue conversion in the heart with these microRNAs, which may be more practical for direct delivery into cells and allow for possible development of therapies without using genetic methods or transplantation of stem cells.”

The researchers said using microRNA for tissue regeneration has several potential advantages over genetic methods or transplantation of stem cells, which have been difficult to manage inside the body. Notably, the microRNA process eliminates technical problems such as genetic alterations, while also avoiding the ethical dilemmas posed by stem cells.

“It’s an exciting stage for reprogramming science,” said Tilanthi M. Jayawardena, PhD, first author of the study. “It’s a very young field, and we’re all learning what it means to switch a cell’s fate. We believe we’ve uncovered a way for it to be done, and that it has a lot of potential.”

Go here to see the original:
Duke Team Turns Scar Tissue into Heart Muscle Without Using Stem Cells

Duke team turns scar tissue into heart muscle without using stem cells

Public release date: 26-Apr-2012 [ | E-mail | Share ]

Contact: Sarah Avery sarah.avery@duke.edu 919-660-1306 Duke University Medical Center

DURHAM, N.C. Scientists at Duke University Medical Center have shown the ability to turn scar tissue that forms after a heart attack into heart muscle cells using a new process that eliminates the need for stem cell transplant.

The study, published online April 26 in the journal Circulation Research, used molecules called microRNAs to trigger the cardiac tissue conversion in a lab dish and, for the first time, in a living mouse, demonstrating the potential of a simpler process for tissue regeneration.

If additional studies confirm the approach in human cells, it could lead to a new way for treating many of the 23 million people worldwide who suffer heart failure, which is often caused by scar tissue that develops after a heart attack. The approach could also have benefit beyond heart disease.

“This is a significant finding with many therapeutic implications,” said Victor J. Dzau, M.D., a senior author on the study who is James B. Duke professor of medicine and chancellor of health affairs at Duke University. “If you can do this in the heart, you can do it in the brain, the kidneys and other tissues. This is a whole new way of regenerating tissue.”

To initiate the regeneration, Dzau’s team at Duke used microRNAs, which are molecules that serve as master regulators controlling the activity of multiple genes. Tailored in a specific combination, the microRNAs were delivered into scar tissue cells called fibroblasts, which develop after a heart attack and impair the organ’s ability to pump blood.

Once deployed, the microRNAs reprogrammed fibroblasts to become cells resembling the cardiomyocytes that make up heart muscle. The Duke team not only proved this concept in the laboratory, but also demonstrated that the cell conversion could occur inside the body of a mouse a major requirement for regenerative medicine to become a potential therapy.

“This is one of the exciting things about our study,” said Maria Mirotsou, PhD, assistant professor of cardiology at Duke and a senior author of the study. “We were able to achieve this tissue conversion in the heart with these microRNAs, which may be more practical for direct delivery into cells and allow for possible development of therapies without using genetic methods or transplantation of stem cells.”

The researchers said using microRNA for tissue regeneration has several potential advantages over genetic methods or transplantation of stem cells, which have been difficult to manage inside the body. Notably, the microRNA process eliminates technical problems such as genetic alterations, while also avoiding the ethical dilemmas posed by stem cells.

Excerpt from:
Duke team turns scar tissue into heart muscle without using stem cells

Stem cell researchers map new knowledge about insulin production

Public release date: 26-Apr-2012 [ | E-mail | Share ]

Contact: Professor Palle Serup palle.serup@sund.ku.dk 01-145-402-20026 University of Copenhagen

Scientists from The Danish Stem Cell Center (DanStem) at the University of Copenhagen and Hagedorn Research Institute have gained new insight into the signaling paths that control the body’s insulin production. This is important knowledge with respect to their final goal: the conversion of stem cells into insulin-producing beta cells that can be implanted into patients who need them. The research results have just been published in the well-respected journal PNAS.

Insulin is a hormone produced by beta cells in the pancreas. If these beta cells are defective, the body develops diabetes. Insulin is vital to life and therefore today the people who cannot produce their own in sufficient quantities, or at all, receive carefully measured doses often via several daily injections. Scientists hope that in the not-so-distant future it will be possible to treat diabetes more effectively and prevent secondary diseases such as cardiac disease, blindness and nerve and kidney complications by offering diabetes patients implants of new, well-functioning, stem-cell-based beta cells.

“In order to get stem cells to develop into insulin-producing beta cells, it is necessary to know what signaling mechanisms normally control the creation of beta cells during fetal development. This is what our new research results can contribute,” explains Professor Palle Serup from DanStem.

“When we know the signaling paths, we can copy them in test tubes and thus in time convert stem cells to beta cells,” says Professor Serup.

The new research results were obtained in a cooperative effort between DanStem, the Danish Hagedorn Research Institute and international partners in Japan, Germany, Korea and the USA. The scientific paper has just been published in the well-respected international journal PNAS (Proceedings of the National Academy of Sciences of the United States of America) entitled Mind bomb 1 is required for pancreatic -cell formation.

Better control of stem cells

The signaling mechanism that controls the first steps of the development from stem cells to beta cells has long been known.

“Our research contributes knowledge about the next step in development and the signaling involved in the communication between cells an area that has not been extensively described. This new knowledge about the ability of the so-called Notch signaling first to inhibit and then to stimulate the creation of hormone-producing cells is crucially important to being able to control stem cells better when working with them in test tubes,” explains Professor Palle Serup .

More here:
Stem cell researchers map new knowledge about insulin production

Biz Beat: Making stem cells "available to the masses"

Mike Ivey writes on all matters money in the spirit of Capital Times founder William T. Evjue, who believed that the concentration of wealth in the U.S. is not healthy for the Democracy.

When UW-Madison’s James Thomson in 1998 became the first scientist to grow human embryonic stem cells in a lab, it generated tremendous excitement about the medical possibilities.

Thomson tried to downplay the breakthrough but talk spread about cures for Alzheimers or Parkinsons disease, growing livers for cirrhosis suffers or producing healthy heart cells for cardiac patients.

The miracle cures have been slow in coming, however. Scientists can replicate healthy nerve cells in a Petri dish but havent found a way to replace defective spinal cells in ALS victims, for example.

In many ways, were still at the first steps,Anita Bhattacharyya, a senior scientist in the stem cell program at the UW’s Waisman Center, told a business group Tuesday.

Butproducing stem cells for others to use is proving one of Madisons more promising new business ventures. Pharmaceutical companies in particular are using stem cells to test drugs before launching into expensive further testing.

Were making these cells available to the masses, says Chris Parker, chief technology officer at Cellular Dynamics International.

Launched by Thomson — and backed with $100 million from a local investor group — Cellular Dynamics International was lauded recently by MIT as one of the 50 most important companies in the world

Since its founding in 2005, the company now counts 107 employees at it offices in University Research Park and is continuing to grow.

Im hiring right now, Parker joked toa lunch crowd of the Wisconsin Technology Council Tuesday.

Continued here:
Biz Beat: Making stem cells "available to the masses"

Transforming scar tissue into beating heart muscle may help repair cardiac damage

London, Apr 19 : Researchers including one of Indian origin have declared a research breakthrough in mice that shows promise to restore hearts damaged by heart attacks-by converting scar-forming cardiac cells into beating heart muscle.

Gladstone Institutes scientists previously transformed such cells into cardiac muscle-like cells in petri dishes.

But Gladstone postdoctoral scholar Li Qian, PhD, along with researchers in the laboratory of Deepak Srivastava, MD, has now accomplished this transformation in living animals-and with even greater success.

The results may have broad human-health implications.

“The damage from a heart attack is typically permanent because heart-muscle cells-deprived of oxygen during the attack-die and scar tissue forms,” said Dr. Srivastava, who directs cardiovascular and stem cell research at Gladstone, an independent and nonprofit biomedical-research institution.

“But our experiments in mice are a proof of concept that we can reprogram non-beating cells directly into fully functional, beating heart cells-offering an innovative and less invasive way to restore heart function after a heart attack.”

In laboratory experiments with mice that had experienced a heart attack, Drs. Qian and Srivastava delivered three genes that normally guide embryonic heart development-together known as GMT-directly into the damaged region.

Within a month, non-beating cells that normally form scar tissue transformed into beating heart-muscle cells. Within three months, the hearts were beating even stronger and pumping more blood.

“These findings could have a significant impact on heart-failure patients-whose damaged hearts make it difficult for them to engage in normal activities like walking up a flight of stairs,” said Dr. Qian, who is also a California Institute for Regenerative Medicine postdoctoral scholar and a Roddenberry Fellow.

“This research may result in a much-needed alternative to heart transplants-for which donors are extremely limited. And because we are reprogramming cells directly in the heart, we eliminate the need to surgically implant cells that were created in a petri dish.”

Read the original here:
Transforming scar tissue into beating heart muscle may help repair cardiac damage

Expert wants central bank for cord blood

A nodal public stem-cell bank in India is the need of the hour if blood cancer and thalassaemia patients are to benefit from stem-cell therapy, according to an expert.

We need an indigenous inventory of 30,000 units of umbilical cord-blood stem-cells, which would enable seven out of 10 patients seeking stem-cell transplant to find a ready match off the shelves, said P. Srinivasan, a pioneer in public cord-blood banking in the country, addressing members of the Ladies Study Group of the Indian Chamber of Commerce on Friday.

Cord blood, also called placental blood, is the blood remaining in the umbilical cord and placenta following childbirth after the cord is cut, and is routinely discarded with the placenta and umbilical cord as biological waste.

A rich source of stem cells, cord blood can be used to treat over 80 diseases, including certain cancers like leukaemia, breast cancer, blood disorders like thalassaemia major and autoimmune disorders like lupus, multiple sclerosis, Crohns Disease and rheumatoid arthritis.

Early clinical studies suggest these can even help avert corneal degeneration and restore vision in cases of blindness, help restore proper cardiac function to heart attack sufferers and improve movement in patients with spinal cord injury.

Since stem-cell matching is highly ethnicity dependent, the chances of an Indian finding a perfect match in a foreign country is a lot less compared to a resource pool of locally-donated units, the former resource person for WHO, now the chairman and managing trustee of Jeevan Blood Bank and Research Centre in Chennai, added.

Even if someone finds a match abroad, the cost of shipping the bag of matching cord blood could be as high as $40,000, as against the Rs 30,000 required for processing and storing one unit indigenously.

Srinivasan felt reaching the critical mass of 30,000 cord-blood units wasnt a big deal, given the fact that 20 million babies are born in India every year.

Purnima Dutta, the president of Ladies Study Group, agreed that raising awareness on the need to donate umbilical cord blood was the key.

As women and responsible citizens, the onus is on us to spread the word and encourage young couples to come forward and donate cord blood to ensure we can achieve this desired public-bank inventory which can save valuable lives, she said.

Read more from the original source:
Expert wants central bank for cord blood

Bioheart Labs and Stemlogix Veterinary Products Featured in Media

SUNRISE, Fla., March 22, 2012 (GLOBE NEWSWIRE) — Bioheart, Inc. (OTCBB:BHRT.OB – News), a company focused on developing stem cell therapies for heart disease, previously announced that they entered into an agreement with Stemlogix, LLC, a veterinary regenerative medicine company, to provide additional cellular products and services to the veterinary market. Under this agreement, the companies are offering stem cell banking for veterinary patients (pets). WPLG, channel 10 featured this exciting technology in a news segment which aired in the South Florida area. A small sample of tissue can be obtained from the animals during a routine procedure such as a spay or neuter. The stem cells are isolated and cryopreserved for future use as needed.

“We are excited to bring our expertise in stem cell therapy to the veterinary community,” said Mike Tomas, Bioheart’s President and CEO. “Stem cell therapies represent new opportunities for various types of patients and the ability to bank a pet’s cells when they are young and healthy could be very valuable for future use.”

WPLG, Channel 10 in Miami/South Florida featured this new technology in a news segment which aired March 15, 2012. Please see the link below:

http://www.local10.com/thats-life/health/Pet-stem-cells-frozen-banked-for-future-use/-/1717022/9285894/-/apcx9rz/-/index.html

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.

About Stemlogix, LLC

Stemlogix is an innovative veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the best possible stem cell therapy to dogs, cats and horses at the point-of-care. Stemlogix provides veterinarians with the ability to isolate regenerative stem cells from a patient’s own adipose (fat) tissue directly on-site within their own clinic or where a patient is located. Regenerative stem cells isolated from adipose tissue have been shown in studies to be effective in treating animal’s suffering from osteoarthritis, joint diseases, tendon injuries, heart disorders, among other conditions. Stemlogix has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. For more information about veterinary regenerative medicine please visit http://www.stemlogix.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

See more here:
Bioheart Labs and Stemlogix Veterinary Products Featured in Media

Research and Markets: Progenitor and Stem Cell Technologies and Therapies Reviews the Range Of Progenitor and Stem …

DUBLIN–(BUSINESS WIRE)–Dublin – Research and Markets (http://www.researchandmarkets.com/research/2fee68d4/progenitor_and_ste) has announced the addition of Woodhead Publishing Ltd’s new book “Progenitor and Stem Cell Technologies and Therapies” to their offering.

Progenitor and stem cell technologies and therapies

Progenitor and stem cells have the ability to renew themselves and change into a variety of specialised types, making them ideal materials for therapy and regenerative medicine. “Progenitor and stem cell technologies and therapies” reviews the range of progenitor and stem cells available and their therapeutic application.

Part one reviews basic principles for the culture of stem cells before discussing technologies for particular cell types. These include human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells. Part two discusses wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies. The final part of the book considers the therapeutic use of stem and progenitor cells. Chapters review the use of adipose tissue-derived stem cells, umbilical cord blood (UCB) stem cells, bone marrow, auditory and oral cavity stem cells. Other chapters cover the use of stem cells in therapies in various clinical areas, including lung, cartilage, urologic, nerve and cardiac repair.

With its distinguished editor and international team of contributors, “Progenitor and stem cell technologies and therapies” is a standard reference for both those researching in cell and tissue biology and engineering as well as medical practitioners investigating the therapeutic use of this important technology.

Key Features:

– Reviews the range of progenitor and stem cells available and outlines their therapeutic application

– Examines the basic principles for the culture of stem cells before discussing technologies for particular cell types, including human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells

– Includes a discussion of wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies

For more information visit http://www.researchandmarkets.com/research/2fee68d4/progenitor_and_ste

Originally posted here:
Research and Markets: Progenitor and Stem Cell Technologies and Therapies Reviews the Range Of Progenitor and Stem …

This Week in JAMA [This Week in JAMA]

Dexmedetomidine for Maintaining Sedation

During prolonged mechanical ventilation, sedation with midazolam or propofol is associated with serious adverse effects. Jakob and colleagues assessed the efficacy of dexmedetomidinean 2-agonist sedativecompared with either midazolam or propofol in 2 multicenter randomized trials that involved 998 patients expected to require more than 24 hours’ mechanical ventilation. Among the authors’ findings was that dexmedetomidine was not inferior to midazolam or propofol in maintaining light to moderate sedation or in reducing total ventilation duration compared with midazolam. However, dexmedetomidine was associated with more adverse events. In an editorial, Wunsch discusses the costs and benefits of sedative options for critically ill patients undergoing mechanical ventilation.

(ARTICLE) (ARTICLE)

Epinephrine is widely used in resuscitation of patients with out-of-hospital cardiac arrest; however, its effectiveness is not established. Hagihara and colleagues analyzed registry data from 417188 patients with out-of-hospital cardiac arrest to assess the relationship between prehospital epinephrine use and mortality and functional status among survivors. The authors report that prehospital epinephrine use was associated with increased return of spontaneous circulation before hospital arrival but decreased the likelihood of survival at 1 month or survival with good functional status. In an editorial, Callaway discusses the evidence that epinephrine use during cardiopulmonary resuscitation may not improve patient-oriented outcomes.

(ARTICLE) (ARTICLE)AND AUTHOR AUDIO INTERVIEW

Immunosuppressive induction therapyroutine in organ transplantsreduces the risk of organ rejection but is associated with adverse effects. Infusion of bone marrowderived mesenchymal stem cells, which have immunoregulatory effects, may offer an alternative immunosuppressive approach. In a randomized trial of 159 patients undergoing living-related kidney transplants, Tan and colleagues found that compared with conventional antiinterleukin 2 receptor antibodybased therapy, a regimen that involved infusion of autologous mesenchymal stem cells was associated with a lower incidence of acute rejection and better renal function at 1 year.

(ARTICLE)

The use of anesthesiologists or nurse anesthetists to administer procedural sedation during outpatient endoscopies increases costs. In a retrospective analysis of claims data from 1.1 million Medicare beneficiaries and 5.5 million commercially insured patients, Liu and colleagues found that utilization of anesthesia services during upper endoscopies and colonoscopies increased from approximately 14% in 2003 to more than 30% in 2009. The majority of anesthesia services were provided to low-risk patients and varied across geographic regions. In an editorial, Fleisher discusses factors that may contribute to increased use of anesthesia services for patients undergoing endoscopy procedures.

(ARTICLE) (ARTICLE)AND AUTHOR VIDEO INTERVIEW

Mrs N, a 75-year-old woman, has a several-year history of hearing loss, which is more bothersome to her family than herself. Pacala and Yueh discuss the prevalence, etiology, and consequences of hearing loss in older patients; its evaluation and treatment, including the selection and fitting of hearing aids; and special challenges to effective hearing aid use among older adults with multiple comorbidities.

Read more from the original source:
This Week in JAMA [This Week in JAMA]

Pluristem reports success in stem cell heart attack treatment

Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) today announced that its PLacental eXpanded (PLX) cells improve several parameters in acute myocardial infarction (heart attacks) in animals. The preclinical trial was conducted at the Center for Regenerative Therapies in Germany.

The trial included 20 mice, which were given induced heart attacks. Half the mice were then given either PLX cells, and the other half were given a cell-free medium as a control. Five other mice underwent a sham (placebo) operation. After four weeks, the mice underwent an ECG, and were then killed for a physical examination of their hearts. The mice which received PLX had improved cardiac muscle function compared with the control group.

Study leader Prof. Christof Stamm said, “As a cardiac surgeon, the unique ability demonstrated by Pluristem’s PLX cells for the treatment of heart disease is very exciting.” He added, “PLX cells showed promising results in the AMI studies.”

Pluristem chairman and CEO Zami Aberman said, “These results demonstrate the potential benefits of our cells for use in the treatment of ischemic heart disease, a multi-billion dollar annual market, and one in which many pharmaceutical companies are constantly looking to provide patients with innovative and effective solutions. In addition to moving ahead with our AMI trial, we look forward to continuing to work on finding cell therapy solutions for numerous debilitating diseases.”

An article in the New England Journal of Medicine states that 624,000 patients suffer an acute myocardial infarction annually in the US, a number that will most likely increase with the rising prevalence of obesity, diabetes and the aging of the population.

Pluristem’s share price rose 5.1% by mid-afternoon on the TASE today to NIS 8.50, after closing at $2.15 on Nasdaq yesterday, giving a market cap of $95 million. The share is up 6.5% in premarket trading on Nasdaq today.

Published by Globes [online], Israel business news – http://www.globes-online.com – on March 20, 2012

Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Originally posted here:
Pluristem reports success in stem cell heart attack treatment

This Week in JAMA [This Week in JAMA]

Dexmedetomidine for Maintaining Sedation

During prolonged mechanical ventilation, sedation with midazolam or propofol is associated with serious adverse effects. Jakob and colleagues assessed the efficacy of dexmedetomidinean 2-agonist sedativecompared with either midazolam or propofol in 2 multicenter randomized trials that involved 998 patients expected to require more than 24 hours’ mechanical ventilation. Among the authors’ findings was that dexmedetomidine was not inferior to midazolam or propofol in maintaining light to moderate sedation or in reducing total ventilation duration compared with midazolam. However, dexmedetomidine was associated with more adverse events. In an editorial, Wunsch discusses the costs and benefits of sedative options for critically ill patients undergoing mechanical ventilation.

(ARTICLE) (ARTICLE)

Epinephrine is widely used in resuscitation of patients with out-of-hospital cardiac arrest; however, its effectiveness is not established. Hagihara and colleagues analyzed registry data from 417188 patients with out-of-hospital cardiac arrest to assess the relationship between prehospital epinephrine use and mortality and functional status among survivors. The authors report that prehospital epinephrine use was associated with increased return of spontaneous circulation before hospital arrival but decreased the likelihood of survival at 1 month or survival with good functional status. In an editorial, Callaway discusses the evidence that epinephrine use during cardiopulmonary resuscitation may not improve patient-oriented outcomes.

(ARTICLE) (ARTICLE)AND AUTHOR AUDIO INTERVIEW

Immunosuppressive induction therapyroutine in organ transplantsreduces the risk of organ rejection but is associated with adverse effects. Infusion of bone marrowderived mesenchymal stem cells, which have immunoregulatory effects, may offer an alternative immunosuppressive approach. In a randomized trial of 159 patients undergoing living-related kidney transplants, Tan and colleagues found that compared with conventional antiinterleukin 2 receptor antibodybased therapy, a regimen that involved infusion of autologous mesenchymal stem cells was associated with a lower incidence of acute rejection and better renal function at 1 year.

(ARTICLE)

The use of anesthesiologists or nurse anesthetists to administer procedural sedation during outpatient endoscopies increases costs. In a retrospective analysis of claims data from 1.1 million Medicare beneficiaries and 5.5 million commercially insured patients, Liu and colleagues found that utilization of anesthesia services during upper endoscopies and colonoscopies increased from approximately 14% in 2003 to more than 30% in 2009. The majority of anesthesia services were provided to low-risk patients and varied across geographic regions. In an editorial, Fleisher discusses factors that may contribute to increased use of anesthesia services for patients undergoing endoscopy procedures.

(ARTICLE) (ARTICLE)AND AUTHOR VIDEO INTERVIEW

Mrs N, a 75-year-old woman, has a several-year history of hearing loss, which is more bothersome to her family than herself. Pacala and Yueh discuss the prevalence, etiology, and consequences of hearing loss in older patients; its evaluation and treatment, including the selection and fitting of hearing aids; and special challenges to effective hearing aid use among older adults with multiple comorbidities.

Original post:
This Week in JAMA [This Week in JAMA]

Pluristem reports success in stem cell heart attack treatment

Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) today announced that its PLacental eXpanded (PLX) cells improve several parameters in acute myocardial infarction (heart attacks) in animals. The preclinical trial was conducted at the Center for Regenerative Therapies in Germany.

The trial included 20 mice, which were given induced heart attacks. Half the mice were then given either PLX cells, and the other half were given a cell-free medium as a control. Five other mice underwent a sham (placebo) operation. After four weeks, the mice underwent an ECG, and were then killed for a physical examination of their hearts. The mice which received PLX had improved cardiac muscle function compared with the control group.

Study leader Prof. Christof Stamm said, “As a cardiac surgeon, the unique ability demonstrated by Pluristem’s PLX cells for the treatment of heart disease is very exciting.” He added, “PLX cells showed promising results in the AMI studies.”

Pluristem chairman and CEO Zami Aberman said, “These results demonstrate the potential benefits of our cells for use in the treatment of ischemic heart disease, a multi-billion dollar annual market, and one in which many pharmaceutical companies are constantly looking to provide patients with innovative and effective solutions. In addition to moving ahead with our AMI trial, we look forward to continuing to work on finding cell therapy solutions for numerous debilitating diseases.”

An article in the New England Journal of Medicine states that 624,000 patients suffer an acute myocardial infarction annually in the US, a number that will most likely increase with the rising prevalence of obesity, diabetes and the aging of the population.

Pluristem’s share price rose 5.1% by mid-afternoon on the TASE today to NIS 8.50, after closing at $2.15 on Nasdaq yesterday, giving a market cap of $95 million. The share is up 6.5% in premarket trading on Nasdaq today.

Published by Globes [online], Israel business news – http://www.globes-online.com – on March 20, 2012

Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Continue reading here:
Pluristem reports success in stem cell heart attack treatment

State: Second doctor's license restricted for performing stem cell treatment on patient who died

Dr. Konstantine K. Yankopolus

The state Department of Health restricted a second doctor’s license for working under the direction of Dr. Zannos Grekos in performing a stem cell treatment and for falsifying a medical report after a patient died, according to the state order.

The emergency license restriction is against Dr. Konstantine K. Yankopolus, 3880 Colonial Blvd., Suite 2, Fort Myers, according to the order issued by the state health department late Monday.

The restriction only prohibits Yankopolus from doing anything with stem cells. After a career as an obstetrician/gynecologist, he is now in general practice.

“We attempted a life-saving procedure on a very sick patient and it didn’t go well,” Yankopolus said Monday night. “Our motivation was pure the patient had no other option.”

The state’s action comes on the heels of Grekos attorney last week issuing a statement that another doctor, and not his client, was involved in the treatment of a 77-year-old Indiana man who died March 2. Grekos attorney also denied that a stem cell treatment was performed, only liposuction.

The state health department suspended Grekos license after the death, saying Grekos violated an earlier restriction that he not to do anything with stem cells or bone marrow aspirate in his practice at 9500 Bonita Beach Road, Suite 310.

Lee County sheriff’s authorities identified the man as Richard Poling, of Newburgh, Ind. The Sheriff’s Office also is conducting a criminal probe.

Grekos has been under state scrutiny by state health regulators for well over a year when an earlier patient, a 66-year-old breast cancer patient, went to him for stem cell treatment in 2010 for neurological problems. She later fell, suffered severe brain damage and was taken off life support. After her death, the state ordered Grekos not to do anything with stem cells or bone marrow aspirate in his practice.

The restriction did not prohibit him from conducting educational seminars in the community about stem cell therapy or from arranging for patients to go for the treatment in the Dominican Republic.

More:
State: Second doctor's license restricted for performing stem cell treatment on patient who died

Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs

SUNRISE, Fla., March 15, 2012 (GLOBE NEWSWIRE) — Bioheart, Inc. (BHRT.OB) announced today that it has successfully conducted a laboratory training course in partnership with the Ageless Regenerative Institute, an organization dedicated to the standardization of cell regenerative medicine. The attendees participated in hands on, in depth training in laboratory practices in stem cell science.

“We had students from all over the world attend this first course including physicians, laboratory technicians and students,” said Mike Tomas, Bioheart’s President and CEO. “Bioheart is pleased to be able to share our 13 years of experience in stem cell research and help expand this growing life science field.”

The course included cell culture techniques and quality control testing such as flow cytometry and gram stain. In addition, participants learned how to work in a cleanroom operating according to FDA cGMP standards, regulations used in the manufacture of pharmaceuticals, food and medical devices. Aseptic techniques were also taught as well as cleanroom gowning, environmental monitoring and maintenance.

Future courses are open to physicians, laboratory technicians and students. After graduating the course, attendees are prepared to pursue research and careers in the field of stem cells and regenerative medicine. For more information about the course, contact info@agelessregen.com.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.

About Ageless Regenerative Institute, LLC

The Ageless Regenerative Institute (ARI) is an organization dedicated to the standardization of cell regenerative medicine. The Institute promotes the development of evidence-based standards of excellence in the therapeutic use of adipose-derived stem cells through education, advocacy, and research. ARI has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. ARI has successfully treated hundreds of patients utilizing these cellular therapies demonstrating both safety and efficacy. For more information about regenerative medicine please visit http://www.agelessregen.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Read the original post:
Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs

Gladstone director receives 2012 Abraham White Scientific Achievement Award

Public release date: 15-Mar-2012 [ | E-mail | Share ]

Contact: Diane Schrick diane.schrick@gladstone.ucsf.edu 415-734-2538 Gladstone Institutes

SAN FRANCISCO, CAMarch 15, 2012Gladstone Institutes Senior Investigator Deepak Srivastava, MD has won the prestigious 2012 Abraham White Scientific Achievement Award from The George Washington University. Dr. Srivastava, who directs cardiac and stem cell research at Gladstone will share the award with Dr. Luigina Romani, professor of microbiology at the University of Perugia.

Dr. Srivastava is being recognized for his findings concerning how the protein thymosin beta 4 is vital to protect and repair cells that become damaged in a heart attackpointing the way to its potential use in treating cardiac disease. His research has shown that thymosin beta 4 is not only critical to the development of a heart, but that it also prevents heart cells from dyingwhile stimulating new blood vessels to form.

“Dr. Srivastava’s pioneering studies and scientific contributions have significantly advanced our understanding of the role of thymosin beta 4 in the development and function of the human heart,” said Allan Goldstein, PhD, professor and emeritus chairman of The George Washington University. “His studies have provided the scientific foundation for the potential use of thymosin beta 4 to treat heart attacks and other heart diseases.”

Dr. Srivastava, who joined Gladstone in 2005, uses modern genetic and stem cell technologies to identify the molecular events that instruct progenitor cells to become cardiac cellsand subsequently fashion a functioning heart. In addition to his research with thymosin beta 4, Dr. Srivastava and his lab have successfully reprogrammed connective tissue in the heart directly into beating heart cellsa process that may help regenerate damaged heart muscle.

“Heart disease is the leading cause of death in the United States and basic research in this field is vital to identifying and understanding the causes of human heart disease,” said Dr. Srivastava, who is also a professor of pediatrics, biochemistry and biophysics at the University of California, San Francisco (UCSF), with which Gladstone is affiliated. “I am honored to receive this award and hope our efforts ultimately lead to important new treatments for patients with heart conditions.”

George Washington University presents the Abraham White Scientific Achievement Award annually to honor individuals who have made unique contributions to science and medicine. Notable past recipients include Nobel laureates Bengt Samuelsson, MD, Julius Axelrod, MD, Michael Brown, MD, Joseph Goldstein, MD and Tim Hunt, PhD in addition to a number of other distinguished scientists. The award will be presented today at a special ceremony in Washington D.C.

“We are delighted that George Washington University has acknowledged Dr. Srivastava’s exceptional achievements in the field of cardiovascular research,” said Gladstone President R. Sanders Williams, MD. “He richly deserves this recognition due to the creativity and innovation evident in his workand because of its potential to benefit the millions of individuals suffering from cardiac disorders.”

Before joining Gladstone, Dr. Srivastava was a professor in the department of pediatrics and molecular biology at the University of Texas Southwestern (UTSW) Medical Center in Dallas. He has received numerous honors and awards, including endowed chairs at UTSW and UCSF, as well as election to the American Society for Clinical Investigation, the Society for Pediatric Research, the American Academy of Arts and Sciences and the American Association for the Advancement of Science.

Link:
Gladstone director receives 2012 Abraham White Scientific Achievement Award

Heart Disease Stem Cell Therapies – Development Must Come From Several Specialties

Editor’s Choice Academic Journal Main Category: Heart Disease Also Included In: Cardiovascular / Cardiology;Stem Cell Research Article Date: 09 Mar 2012 – 4:00 PST

email to a friend printer friendly opinions

Current Article Ratings:

The paper’s lead author, Kenneth Chien from Harvard University in the USA explains:

Until now, clinical trials have been based on heart attacks, chronic heart failure as well as dilated cardiomyopathy, but regardless of the fact that regenerative therapies that are based on various non-cardiac cell types seem to be safe, their efficacy has not yet been tested in a clinical trial.

However, possible new targets and treatment strategies are now emerging due to recent progress in cardiac stem cell research and regenerative biology.

Scientists used to think that the heart only has a minimal capacity for self-renewal and saw no prospect in reversing the loss of healthy heart muscle and function. This perception has been altered because of recent findings, such as the discovery of several distinct embryonic progenitor cell types of which some are found in the heart.

A certain number of these cells can be activated in people with cardiac injuries and are now targeted by scientists to develop novel cardiac regenerative therapeutics either by delivery of the cells, or by new methods that activate expansion and conversion of functioning heart cells.

For instance, clinical studies conducted a short while ago demonstrated that scar formation following a heart attack can be reduced by taking cells from the patient’s own heart tissue. Even though it remains uncertain whether the delivered cells are indeed stem cells, these studies nevertheless demonstrate that this is a small, educational step towards the goal of utilizing the heart’s potential for self-healing.

There is still a lot of work to be done. The complexity of the heart means that in order to restore its function requires more than just regenerating one cell type, it also means that the native structure of the heart needs to be recreated.

View original post here:
Heart Disease Stem Cell Therapies – Development Must Come From Several Specialties

Stem Cells

Stem cells are widely researched for their therapeutic use. An important potential application of human stem cells, through a more complete understanding of the genetic and molecular controls of cell division and differentiation, is the generation of cells and tissues that could be used for cell-based therapies. The use of embryonic and adult-derived stem cells for cardiac repair is a particularly active area of research. The first Series paper highlights insights gained from clinical trials of adult stem cells, together with fundamental scientific advances in cardiac stem cell and regenerative biology. New targets and strategies for regenerative therapies are being identified, including discoveries related to intrinsic cardiac regeneration, renewal factors that can trigger regeneration, and tissue-engineering technology. These discoveries are beginning to change the way investigators view the scientific and clinical position of cardiovascular regenerative therapy. Furthermore, advances in tissue engineering and regenerative medicine have established a foundation on which the functional replacement of whole organs and complex tissues such as skeletal muscle, trachea, and oesophagus seems possible.

The second paper discusses a novel approach for the replacement of complex tissues and whole organs involving the use of three-dimensional biological scaffolds made of allogeneic or xenogeneic extracellular matrix derived from non-autologous sources. End-stage organ failure is a key challenge for the medical community because of the ageing population and the severe shortage of suitable donor organs available. Equally, few therapeutic options are available for injuries to or congenital absence of complex tissues such as the trachea, oesophagus, or skeletal muscle. Three-dimensional extracellular matrix scaffolds populated with autologous cells have been used successfully for the repair and reconstruction of complex tissues and provide a promising basis for the engineering of whole organs and other tissues.

Stephen F Badylak, Daniel J Weiss, Arthur Caplan, Paolo Macchiarini

Read more:
Stem Cells

Stem Cell-Seeded Cardiopatch Could Deliver Results for Damaged Hearts

Durham, NC (PRWEB) March 07, 2012

A new type of stem cell-seeded patch has shown promising results in promoting healing after a heart attack, according to a study released today in the journal STEM CELLS Translational Medicine.

Ischemic heart disease, caused by vessel blockage, is a leading cause of death in many western countries. Studies have shown the potential of stem cells in regenerating heart tissue damaged during an attack. But even as the list of candidate cells for cardiac regeneration has expanded, none has emerged as the obvious choice, possibly because several cell types are needed to regenerate both the hearts muscles and its vascular components.

Aside from the choice of the right cell source for tissue regeneration, the best way to deliver the stem cells is up for debate, too, as intravenous delivery and injections can be inefficient and possibly harmful. While embryonic stem cells have shown great promise for heart repairs due to their ability to differentiate into virtually any cell type, less than 10 percent of injected cells typically survive the engraftment and of that number generally only 2 percent actually colonize the heart.

In order for this type of treatment is to be clinically effective, researchers need to find ways to deliver large numbers of stem cells in a supportive environment that can help cells survive and differentiate.

In the current cardiopatch study, conducted by researchers from the Faculty of Medicine of the Geneva University in collaboration with colleagues at the Ecole Polytechnique Federale de Lausanne (EPFL), cardiac-committed mouse embryonic stem cell (mESC) were committed toward the cardiac fate using a protein growth factor called BMP2 and then embedded into a fibrin hydrogel that is both biocompatible and biodegradable. The cells were loaded with superparamagnetic iron oxide nanoparticles so they could be tracked using magnetic resonance imaging, which also enabled the researchers to more accurately assess regional and global heart function.

The patches were engrafted onto the hearts of laboratory rats that had induced heart attacks. Six weeks later, the hearts of the animals receiving the mESC-seeded patches showed significant improvement over those receiving patches loaded with iron oxide nanoparticles alone. The patches had degraded, the cells had colonized the infarcted tissue and new blood vessels were forming in the vicinity of the transplanted patch. Improvements reached beyond the part of the heart where the patch had been applied to manifest globally.

Marisa Jaconi, PhD, of the Geneva University Department of Pathology and Immunology, and Jeffrey Hubbell, PhD, professor of bioengineering at the EPFL, were leaders on the investigative team. Their findings could make a significant impact on how heart patients are treated in the future. Altogether our data provide evidence that stem-cell based cardiopatches represent a promising therapeutic strategy to achieve efficient cell implantation and improved global and regional cardiac function after myocardial infarction, said Jaconi.

###

The full article, Embryonic stem cell-based cardiopatches improve cardiac function in infarcted rats, can be accessed at: http://www.stemcellstm.com/content/early/recent.

See more here:
Stem Cell-Seeded Cardiopatch Could Deliver Results for Damaged Hearts

Adult Stem Cells Can Help Cancer..Investigate Stem Cell Options – Video


27-02-2012 13:06 Free E-book /Adult Stem Cell Nutrition http://www.EJMorris.org adult stem cells help arrest Cancer as stated by Dick Van Dyke .. Adult stem cells ( ADC ) Repair damaged heart or brain following heart attack or stroke. Treatment for cardiac damage, brain damage, degenerative brain disease including potential new treatment for Alzheimer’s, multiple sclerosis, Parkinson’s disease, encephalopathy, micro emboli, brain trauma. Experimental treatments to regenerate healthy brain tissue using adult stem cells — rather than embryonic stem cells. Adult stem cells from bone marrow appear to cross the blood brain barrier to form new brain tissue. Adult stem cells from bone marrow also contribute to heart repair, stimulating new cardiac cell development, improving cardiac output. Nerve tissue, neurons, nerve fibers regrow using adult stem cells. Use of adult neural stem cells from the olfactory bulb to treat brain disease, brain injury or spinal cord injury, paralysis. Animal and human experiments to repair brain and spinal cord start to show early promise. Adult stem cells will help in the future management of heart attacks .. the Reversal of neurological damage, neurosurgery, neurology and brain studies. ADC aid in Anti ageing therapies, science and research. More Adult stem cells are needed in blood circulation as we age … 65% of health care spending on people over 65 years old. Aging process — physiology of aging and remedies, anti aging therapies. How to stay young. How we share

Read the original here:
Adult Stem Cells Can Help Cancer..Investigate Stem Cell Options – Video

New Stem Cell Research Shows Promising Results — Advanced Cell Tech and NeoStem Poised to Benefit

NEW YORK, NY–(Marketwire -03/05/12)- February was a challenging month for stem cell stocks. TickerSpy’s Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over the last month — underperforming the S&P 500 by close to 17 percent over that time frame. Despite the drop in investor optimism, new research continues to propel the industry forward. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology, Inc. (OTC.BB: ACTC.OB – News) and NeoStem, Inc. (AMEX: NBS – News). Access to the full company reports can be found at:

http://www.fivestarequities.com/ACTC

http://www.fivestarequities.com/NBS

A new study at Johns Hopkins University has shown that stem cells from patients’ own cardiac tissue can be used to heal scarred tissue after a heart attack. “This has never been accomplished before, despite a decade of cell therapy trials for patients with heart attacks. Now we have done it,” Eduardo Marban, director of the Cedars-Sinai Heart Institute and one of the study’s co-authors, said in a statement. “The effects are substantial.”

In another study, researchers led by Jonathan Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital, argue they’ve discovered the ovaries of young women harbor very rare stem cells capable of producing new eggs.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The Company recently issued a press release stating that it utilized $13.6 million in cash for operations during 2011, compared to $8.8 million in the year-earlier period. The increase in cash utilization resulted primarily from ACT’s ongoing clinical activities in the US and Europe.

NeoStem, Inc., a biopharmaceutical company, engages in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States and China. In January, Amorcyte, LLC, a NeoStem, Inc. company, announced the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

Original post:
New Stem Cell Research Shows Promising Results — Advanced Cell Tech and NeoStem Poised to Benefit

Baxter Initiates Phase III Adult Stem Cell Clinical Trial for Chronic Cardiac Condition

Study Aims to Deliver Adult’s Own Cells As Treatment for Chronic Myocardial Ischemia

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX) announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual’s own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

Chronic myocardial ischemia (CMI) is one of the most severe forms of coronary artery disease, causing significant long-term damage to the heart muscle and disability to the patient. It is often diagnosed based on symptoms of severe, refractory angina, which is severe chest discomfort that does not respond to conventional medical management or surgical interventions.

“The prospect of using a person’s own adult stem cells to restore and repair blood flow in CMI is a very exciting concept based on a biological regenerative approach,” said Norbert Riedel, Ph.D., Baxter’s chief science and innovation officer. “The goals of this phase III trial are aligned with Baxter’s overall mission to develop life-saving and life-sustaining therapies and it will help us determine if the therapy can make a meaningful difference for CMI patients.”

The trial will enroll approximately 450 patients across 50 clinical sites in the United States, who will be randomized to one of three arms: treatment with their own autologous CD34+ stem cells, treatment with placebo (control), or unblinded standard of care. The primary objective is to evaluate the efficacy of treatment with CD34+ stem cells to improve the functional capacity of patients with CMI, as measured by a change in total exercise capacity at 12 months following treatment. Secondary objectives include reduced frequency of angina episodes at 12 months after treatment and the safety of targeted delivery of the cells.

After stem cell mobilization, apheresis (collecting the cells from the body) and cell processing, participants will receive CD34+ stem cells or placebo in a single treatment via 10 intramyocardial injections into targeted areas of the heart tissue. Efficacy will be measured by a change in total exercise capacity during the first year following treatment and safety data will be collected for two years. Stem cell processing will be conducted in GMP facilities in the United States by Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, Inc. To learn more or enroll, visit http://www.renewstudy.com or http://www.clinicaltrials.gov.

This trial is being initiated based on the phase II data, which indicated that injections of patients’ own CD34+ stem cells may improve exercise capacity and reduce reports of angina episodes in patients with chronic, severe refractory angina.

“The phase II trial provided evidence that this strategy, leveraging the body’s own natural repair mechanisms, can improve exercise capacity and reduce chest pain, the first time these endpoints have been achieved in a population of patients who have exhausted conventional treatment options,” said Douglas Losordo, MD, vice president of new therapeutic development at Baxter.

CD34+ cells, which are blood-forming stem cells derived from bone marrow, are comprised of endothelial progenitor cells (EPCs), which develop into new blood vessels. Previous preclinical studies investigating these cells have shown an increase in capillary density and improved cardiac function in models of myocardial ischemia.

About Baxter

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements concerning the use of adult autologous stem cells to treat CMI, including expectations with respect to the related phase III clinical trial. These statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: clinical results demonstrating the safety and effectiveness of the use of autologous stem cells to treat CMI; timely submission of regulatory filings; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; the enrollment of a sufficient number of qualified participants in the phase III clinical trial; the successful provision of stem cell processing by PCT, a third party; and other risks identified in Baxter’s most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50183372&lang=en

See the original post here:
Baxter Initiates Phase III Adult Stem Cell Clinical Trial for Chronic Cardiac Condition

Archives